Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $30
Amylyx Pharmaceuticals, Inc. -5.54%
Amylyx Pharmaceuticals, Inc. AMLX | 16.36 | -5.54% |
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:
AMLX) with a Buy and raises the price target from $25 to $30.
